Skip to main content

Table 1 Included studies of antiplatelet use in HD patients: Study design, treatments, intervention, bleeding events (A: Aspirin P: Placebo S: Sulfinpyrazone C: Control Cl: Clopidogrel A + Cl: Aspirin + Clopidogrel D: Dipyramidole A + D Aspirin + Dipyramidole)

From: The risk of bleeding for antiplatelet agents in Haemodialysis patients: a Meta-analysis

Study

Year

Study design

Control group

Intervention

Bleeding

 

Bleeding events

total

Periods

(months)

Quality score

     

Defined a priori

Defined as used

Bleedings/patients (n/n)

   

Harter

[13]

1979

RCT

Placebo

Aspirin 160 mg od

No

Transfusions

A: 5/19 P: 13/25

44

5

M

Kaegi

[14]

1975

RCT crossover

Placebo

Sulfinpyrazone 200 mg tid

No

GI bleedings

S: 2/45 P: 1/45

45

6

M

Kaufman

[15]

2003

RCT

Placebo

Aspirin 325 mg + Clopidogrel 75 mg daily

Yes

As major, intermediate and minor

A + Cl:44/104

P: 23/96

200

~ 7

H

Kobayashi

[16]

1980

RCT

Placebo

Ticlopidine 100 mg bid

No

Major or serious bleeding

T: 4/47 P: 3/53

100

3

H

Kooistra [17]

1994

RCT

crossover

Placebo

Aspirin 30 mg od

No

Bleeding incidents not due to HD

A:2/137 P:5/137

137

3

M

Liu [18]

2016

Prospective

cohort

Control

Aspirin 100 mg od

Yes

Intracranial hemorrhage, major bleeding events (i.e. gastrointestinal bleeding)

A: 14/152 C:36/254

406

60

6

Obialo

[19]

2003

Prospective

cohort

Control

Aspirin 325 mg od

No

GI bleedings

A: 5/21 C: 0/31

52

~ 4

7

Sreedhara

[20](a)

1994

RCT

Placebo

Dipyramidole 75 mg tid

No

GI adverse events

D: 5/29

P: 2/24

107

72?

L

Sreedhara

[20](b)

  

Placebo

Aspirin 325 mg daily

  

A: 3/26

P: 2/24

107

  

Sreedhara

[20](c)

  

Placebo

Aspirin 325 mg daily + Dipyramidole 75 mg tid

  

A + D: 5/28

P: 2/24

107

  

Tayebi

[21]

2018

RCT

Placebo

Aspirin 80 mg daily + Dipyramidole 75 mg daily

No

Major or serious bleeding

A + D: 2/20

P: 0/20

40

12

H